Skip to main content
Erschienen in: Pediatric Cardiology 5/2015

01.06.2015 | Review Article

Aortic Involvement in Pediatric Marfan syndrome: A Review

verfasst von: Omonigho Ekhomu, Zahra J. Naheed

Erschienen in: Pediatric Cardiology | Ausgabe 5/2015

Einloggen, um Zugang zu erhalten

Abstract

Outlining specific protocols for the management of pediatric patients with Marfan syndrome has been challenging. This is mostly due to a dearth of clinical studies performed in pediatric patients. In Marfan syndrome, the major sources of morbidity and mortality relate to the cardiovascular system. In this review, we focus on aortic involvement seen in pediatric patients with Marfan syndrome, ranging from aortic dilatation to aortic rupture and heart failure. We discuss the histological, morphological, and pathogenetic basis of the cardiac manifestations seen in pediatric Marfan syndrome and use a specific case to depict our experienced range of cardiovascular manifestations. The survival for patients with Marfan syndrome may approach the expected survival for non-affected patients, with optimal management. With this potentiality in mind, we explore possible and actual management considerations for pediatric Marfan syndrome, examining both medical and surgical therapy modalities that can make the possibility of improved survival a reality.
Literatur
1.
Zurück zum Zitat Adams JN, Trent RJ (1998) Aortic complications of Marfan’s syndrome. Lancet 352:1722–1723CrossRefPubMed Adams JN, Trent RJ (1998) Aortic complications of Marfan’s syndrome. Lancet 352:1722–1723CrossRefPubMed
2.
Zurück zum Zitat Ashworth JL, Murphy G, Rock MJ, Sherratt MJ (1999) Fibrillin degradation by matrix metalloproteinases: implication for connective tissue remodelling. Biochem J 340:171–181CrossRefPubMedCentralPubMed Ashworth JL, Murphy G, Rock MJ, Sherratt MJ (1999) Fibrillin degradation by matrix metalloproteinases: implication for connective tissue remodelling. Biochem J 340:171–181CrossRefPubMedCentralPubMed
3.
Zurück zum Zitat Baumgartner D, Baumgartner C, Matayas G, Steinmann B et al (2005) Diagnostic power of aortic elastic properties in young patients with Marfan syndrome. J Thorac Cardiovasc Surg 129:730–739CrossRefPubMed Baumgartner D, Baumgartner C, Matayas G, Steinmann B et al (2005) Diagnostic power of aortic elastic properties in young patients with Marfan syndrome. J Thorac Cardiovasc Surg 129:730–739CrossRefPubMed
4.
Zurück zum Zitat Bechtel JFM, Erasmi AW, Misfeld M, Sievers H (2006) Reconstructive surgery of the aortic valve: the Ross, David, and Yacoub procedures. Herz 31:413–422CrossRefPubMed Bechtel JFM, Erasmi AW, Misfeld M, Sievers H (2006) Reconstructive surgery of the aortic valve: the Ross, David, and Yacoub procedures. Herz 31:413–422CrossRefPubMed
5.
Zurück zum Zitat Bresters D, Nikkels PGJ, Meijboom EJM, Hoorntje TM et al (1999) Clinical, pathological and molecular genetic findings in a case of neonatal Marfan syndrome. Acta Paediatr 88:98–101CrossRefPubMed Bresters D, Nikkels PGJ, Meijboom EJM, Hoorntje TM et al (1999) Clinical, pathological and molecular genetic findings in a case of neonatal Marfan syndrome. Acta Paediatr 88:98–101CrossRefPubMed
6.
Zurück zum Zitat Brooke BS, Habashi JP, Judge DP et al (2008) Angiotensin II blockade and aortic-root dilation in Marfan’s syndrome. N Engl J Med 358(26):2787–2795 Brooke BS, Habashi JP, Judge DP et al (2008) Angiotensin II blockade and aortic-root dilation in Marfan’s syndrome. N Engl J Med 358(26):2787–2795
7.
Zurück zum Zitat Carrel T, Berdat P, Pavlovic M, Sukhanov S et al (2003) Surgery of the dilated aortic root and ascending aorta in pediatric patients: techniques and results. Eur J Cardiothorac Surg 24:249–254CrossRefPubMed Carrel T, Berdat P, Pavlovic M, Sukhanov S et al (2003) Surgery of the dilated aortic root and ascending aorta in pediatric patients: techniques and results. Eur J Cardiothorac Surg 24:249–254CrossRefPubMed
8.
Zurück zum Zitat Chiu H, Wu M, Wang J, Lu C (2013) Losartan Added to ß-blockade therapy for aortic root dilation in Marfan syndrome: a randomized, open-label pilot study. Mayo Clin Proc 88:271–276CrossRefPubMed Chiu H, Wu M, Wang J, Lu C (2013) Losartan Added to ß-blockade therapy for aortic root dilation in Marfan syndrome: a randomized, open-label pilot study. Mayo Clin Proc 88:271–276CrossRefPubMed
9.
Zurück zum Zitat Davis EC (1994) Immunolocalization of microfibril and microfibril-associated proteins in the subendothelial matrix of the developing mouse aorta. J Cell Sci 107:727–736PubMed Davis EC (1994) Immunolocalization of microfibril and microfibril-associated proteins in the subendothelial matrix of the developing mouse aorta. J Cell Sci 107:727–736PubMed
10.
Zurück zum Zitat Della Corte A, Romano G, Tizzano F, Amarelli C et al (2006) Echocardiographic anatomy of ascending aorta dilatation: correlations with aortic valve morphology and function. Int J Cardiol 113:320–326CrossRefPubMed Della Corte A, Romano G, Tizzano F, Amarelli C et al (2006) Echocardiographic anatomy of ascending aorta dilatation: correlations with aortic valve morphology and function. Int J Cardiol 113:320–326CrossRefPubMed
12.
Zurück zum Zitat Dingemans KP, Teeling P, Lagendijk JH, Becker AE (2000) Extracellular matrix of the human aortic media: an ultrastructural histochemical and immunohistochemical study of the adult aortic media. Anat Rec 258:1–14CrossRefPubMed Dingemans KP, Teeling P, Lagendijk JH, Becker AE (2000) Extracellular matrix of the human aortic media: an ultrastructural histochemical and immunohistochemical study of the adult aortic media. Anat Rec 258:1–14CrossRefPubMed
13.
Zurück zum Zitat Elshershari H, Esseid M, Sueblinvong V, Harris C (2014) Angiotensin II receptor blocker slows the rate of progression of aortic root dilatation in Marfan syndrome: two case reports and review of the literature. Congenit Cardiol Today 12(3):1–3 Elshershari H, Esseid M, Sueblinvong V, Harris C (2014) Angiotensin II receptor blocker slows the rate of progression of aortic root dilatation in Marfan syndrome: two case reports and review of the literature. Congenit Cardiol Today 12(3):1–3
15.
Zurück zum Zitat Faivre L, Masurel-Paulet A, Collod-Béroud G, Callewaert BL (2009) Clinical and molecular study of 320 children with Marfan syndrome and related type 1 fibrillinopathies in a series of 1009 probands with pathogenic FBN1 mutations. Pediatrics 123:391–398CrossRefPubMed Faivre L, Masurel-Paulet A, Collod-Béroud G, Callewaert BL (2009) Clinical and molecular study of 320 children with Marfan syndrome and related type 1 fibrillinopathies in a series of 1009 probands with pathogenic FBN1 mutations. Pediatrics 123:391–398CrossRefPubMed
16.
Zurück zum Zitat Fedak PWM, de Sa MPL, Verma S, Nili N et al (2003) Vascular matrix remodeling in patients with bicuspid aortic valve malformations: implications for aortic dilatation. J Thorac Cardiovasc Surg 126(3):805–806CrossRef Fedak PWM, de Sa MPL, Verma S, Nili N et al (2003) Vascular matrix remodeling in patients with bicuspid aortic valve malformations: implications for aortic dilatation. J Thorac Cardiovasc Surg 126(3):805–806CrossRef
17.
Zurück zum Zitat Gao L, Mao Q, Wen D, Zhang L et al (2011) The effect of beta-blocker therapy on progressive aortic dilatation in children and adolescents with Marfan’s syndrome: a meta-analysis. Acta Paediatr 100:e101–e105CrossRefPubMed Gao L, Mao Q, Wen D, Zhang L et al (2011) The effect of beta-blocker therapy on progressive aortic dilatation in children and adolescents with Marfan’s syndrome: a meta-analysis. Acta Paediatr 100:e101–e105CrossRefPubMed
18.
Zurück zum Zitat Gersony DR, McClaughlin M, Zhezhen J, Gersony WM (2007) The effect of beta-blocker therapy on clinical outcome in patients with Marfan’s syndrome: a meta-analysis. Int J Cardiol 303–308 Gersony DR, McClaughlin M, Zhezhen J, Gersony WM (2007) The effect of beta-blocker therapy on clinical outcome in patients with Marfan’s syndrome: a meta-analysis. Int J Cardiol 303–308
19.
Zurück zum Zitat Habashi JP, Judge DP, Holm TM, Cohn RD et al (2006) Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome. Science 312(5770):117–121CrossRefPubMedCentralPubMed Habashi JP, Judge DP, Holm TM, Cohn RD et al (2006) Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome. Science 312(5770):117–121CrossRefPubMedCentralPubMed
20.
Zurück zum Zitat Hartog AW, Franken R, Zwinderman AH, Groenink M et al (2012) Current and future pharmacological treatment strategies with regard to aortic disease in Marfan syndrome. Expert Opin Pharmacother 13(5):647–662CrossRefPubMed Hartog AW, Franken R, Zwinderman AH, Groenink M et al (2012) Current and future pharmacological treatment strategies with regard to aortic disease in Marfan syndrome. Expert Opin Pharmacother 13(5):647–662CrossRefPubMed
21.
Zurück zum Zitat Ikonomidis JS, Jones JA, Barbour JR, Stroud RE et al (2006) Expression of matrix metalloproteinases and endogenous inhibitors within ascending aortic aneurysms of patients with Marfan syndrome. Circulation. 114(Suppl. 1):I-365–I-370 Ikonomidis JS, Jones JA, Barbour JR, Stroud RE et al (2006) Expression of matrix metalloproteinases and endogenous inhibitors within ascending aortic aneurysms of patients with Marfan syndrome. Circulation. 114(Suppl. 1):I-365–I-370
22.
Zurück zum Zitat Jones JA, Ikonomidis JS (2010) The pathogenesis of Aortopathy in Marfan syndrome and related diseases. Curr Cardiol Rep 12:99–107CrossRefPubMed Jones JA, Ikonomidis JS (2010) The pathogenesis of Aortopathy in Marfan syndrome and related diseases. Curr Cardiol Rep 12:99–107CrossRefPubMed
23.
Zurück zum Zitat Keane MG, Pyeritz RE (2008) Medical management of Marfan syndrome. Circulation 117:2802–2813 Keane MG, Pyeritz RE (2008) Medical management of Marfan syndrome. Circulation 117:2802–2813
24.
Zurück zum Zitat Kemna MS, Murphy DJ, Silverman NH (2009) Screening for aortic root dilation in Marfan syndrome using the ratio of the aortic root to descending aortic diameters in children. J Am Soc Echocardiogr 22:1109–1113CrossRefPubMed Kemna MS, Murphy DJ, Silverman NH (2009) Screening for aortic root dilation in Marfan syndrome using the ratio of the aortic root to descending aortic diameters in children. J Am Soc Echocardiogr 22:1109–1113CrossRefPubMed
25.
Zurück zum Zitat Kraseman T, Kotthoff S, Kehl HG et al (2005) Cardiac transplantation in neonatal Marfan syndrome—a life-saving approach. Thorac Cardiov Surg 53(Suppl. 2):S146–S148CrossRef Kraseman T, Kotthoff S, Kehl HG et al (2005) Cardiac transplantation in neonatal Marfan syndrome—a life-saving approach. Thorac Cardiov Surg 53(Suppl. 2):S146–S148CrossRef
26.
Zurück zum Zitat Lacro RV, Guey LT, Dietz HC, Pearson GD (2013) Characteristics of children and young adults with Marfan syndrome and aortic root dilatation in a randomized trial comparing atenolol and losartan therapy. Am Heart J 165:828–835CrossRefPubMedCentralPubMed Lacro RV, Guey LT, Dietz HC, Pearson GD (2013) Characteristics of children and young adults with Marfan syndrome and aortic root dilatation in a randomized trial comparing atenolol and losartan therapy. Am Heart J 165:828–835CrossRefPubMedCentralPubMed
27.
Zurück zum Zitat Ladouceur M, Fermanian C, Lupoglazoff J, Edouard T et al (2007) Effect of beta-blockade on ascending aortic dilatation in children with the Marfan syndrome. Am J Cardiol 99:406–409CrossRefPubMed Ladouceur M, Fermanian C, Lupoglazoff J, Edouard T et al (2007) Effect of beta-blockade on ascending aortic dilatation in children with the Marfan syndrome. Am J Cardiol 99:406–409CrossRefPubMed
28.
Zurück zum Zitat Lazarevic AM, Nakatani S, Okita Y, Marinkovic J et al (2006) Determinants of rapid progression of aortic root dilatation and complications in Marfan syndrome. Int J Cardiol 106:177–182CrossRefPubMed Lazarevic AM, Nakatani S, Okita Y, Marinkovic J et al (2006) Determinants of rapid progression of aortic root dilatation and complications in Marfan syndrome. Int J Cardiol 106:177–182CrossRefPubMed
29.
Zurück zum Zitat Legget ME, Unger TA, O’Sullivan CK, Zwink TR (1996) Aortic root complications in Marfan’s syndrome: identification of a lower risk group. Heart 75:389–395CrossRefPubMedCentralPubMed Legget ME, Unger TA, O’Sullivan CK, Zwink TR (1996) Aortic root complications in Marfan’s syndrome: identification of a lower risk group. Heart 75:389–395CrossRefPubMedCentralPubMed
30.
Zurück zum Zitat Loomba RS, Arora RR (2011) Role of angiotensin receptor blockers for management of aortic dilation associated with Marfan syndrome. Expert Rev Cardiovasc Ther 9(10):1257–1259CrossRefPubMed Loomba RS, Arora RR (2011) Role of angiotensin receptor blockers for management of aortic dilation associated with Marfan syndrome. Expert Rev Cardiovasc Ther 9(10):1257–1259CrossRefPubMed
31.
Zurück zum Zitat Marsalese DL, Moodie DS, Vacante M, Lytle BW, Gill CC et al (1989) Marfan’s syndrome: natural history and long-term follow-up of cardiovascular involvement. J Am Coll Cardiol 14:422–428CrossRefPubMed Marsalese DL, Moodie DS, Vacante M, Lytle BW, Gill CC et al (1989) Marfan’s syndrome: natural history and long-term follow-up of cardiovascular involvement. J Am Coll Cardiol 14:422–428CrossRefPubMed
32.
Zurück zum Zitat Morse RP, Rockenmacher S, Pyeritz RE, Sanders SP (1990) Diagnosis and management of infantile Marfan syndrome. Pediatrics 86:888–895PubMed Morse RP, Rockenmacher S, Pyeritz RE, Sanders SP (1990) Diagnosis and management of infantile Marfan syndrome. Pediatrics 86:888–895PubMed
33.
Zurück zum Zitat Mueller GC, Stierle L, Stark V, Steiner K et al (2014) Retrospective analysis of the effect of angiotensin II receptor blocker versus β-blocker on aortic root growth in paediatric patients with Marfan syndrome. Heart 100:214–218CrossRefPubMed Mueller GC, Stierle L, Stark V, Steiner K et al (2014) Retrospective analysis of the effect of angiotensin II receptor blocker versus β-blocker on aortic root growth in paediatric patients with Marfan syndrome. Heart 100:214–218CrossRefPubMed
34.
Zurück zum Zitat Mullen MJ, Flather MD, Jin XY, Newman WG et al (2013) A prospective, randomized, placebo-controlled, double-blind, multicenter study of the effects of irbesartan on aortic dilatation in Marfan syndrome (AIMS trial): study protocol. Trials 14:408CrossRefPubMedCentralPubMed Mullen MJ, Flather MD, Jin XY, Newman WG et al (2013) A prospective, randomized, placebo-controlled, double-blind, multicenter study of the effects of irbesartan on aortic dilatation in Marfan syndrome (AIMS trial): study protocol. Trials 14:408CrossRefPubMedCentralPubMed
35.
Zurück zum Zitat Niwa K, Perloff JK, Bhuta SM, Laks H et al (2001) Structural abnormalities of great arterial walls in congenital heart disease. Circulation 103:393–400CrossRefPubMed Niwa K, Perloff JK, Bhuta SM, Laks H et al (2001) Structural abnormalities of great arterial walls in congenital heart disease. Circulation 103:393–400CrossRefPubMed
36.
Zurück zum Zitat Patel ND, Weiss ES, Alejo DE, Nwakanma LU et al (2008) Aortic root operations for Marfan syndrome: a comparison of the Bentall and valve-sparing procedures. Ann Thorac Surg 85:2003–2011CrossRefPubMed Patel ND, Weiss ES, Alejo DE, Nwakanma LU et al (2008) Aortic root operations for Marfan syndrome: a comparison of the Bentall and valve-sparing procedures. Ann Thorac Surg 85:2003–2011CrossRefPubMed
37.
Zurück zum Zitat Patel ND, Arnaoutakis GJ, George TJ, Allen JG et al (2011) Valve-sparing aortic root replacement in children: intermediate-term results. Interact CardioVasc Thorac Surg 12:415–419CrossRefPubMed Patel ND, Arnaoutakis GJ, George TJ, Allen JG et al (2011) Valve-sparing aortic root replacement in children: intermediate-term results. Interact CardioVasc Thorac Surg 12:415–419CrossRefPubMed
38.
Zurück zum Zitat Pees C, Laccone F, Hagl M, DeBrauwer V (2013) Usefulness of Losartan on the size of the ascending aorta in an unselected cohort of children, adolescents, and young adults with Marfan syndrome. Am J Cardiol 112:1477–1483CrossRefPubMed Pees C, Laccone F, Hagl M, DeBrauwer V (2013) Usefulness of Losartan on the size of the ascending aorta in an unselected cohort of children, adolescents, and young adults with Marfan syndrome. Am J Cardiol 112:1477–1483CrossRefPubMed
39.
Zurück zum Zitat Pereira L, Andrikopoulos K, Tian J, Lee SY et al (1997) Targetting of the gene encoding fibrillin-1 recapitulates the vascular aspect of Marfan syndrome. Nat Genet 17(2):218–222CrossRefPubMed Pereira L, Andrikopoulos K, Tian J, Lee SY et al (1997) Targetting of the gene encoding fibrillin-1 recapitulates the vascular aspect of Marfan syndrome. Nat Genet 17(2):218–222CrossRefPubMed
40.
Zurück zum Zitat Pettersen MD, Wei D, Skeens M, Humes RA (2008) Regression equations for calculation of z-scores of cardiac structures in a large cohort of healthy infants, children, and adolescents: an echocardiographic study. J Am Soc Echocardiogr 21(8):922–934CrossRefPubMed Pettersen MD, Wei D, Skeens M, Humes RA (2008) Regression equations for calculation of z-scores of cardiac structures in a large cohort of healthy infants, children, and adolescents: an echocardiographic study. J Am Soc Echocardiogr 21(8):922–934CrossRefPubMed
41.
Zurück zum Zitat Pyeritz RE (2009) Marfan syndrome: 30 years of research equals 30 years of additional life expectancy. Heart 95:173–175CrossRefPubMed Pyeritz RE (2009) Marfan syndrome: 30 years of research equals 30 years of additional life expectancy. Heart 95:173–175CrossRefPubMed
42.
Zurück zum Zitat Rakhra SS, Brizard CP, d’Udekem Y, Konstantinov IE (2012) Valve-sparing aortic root replacement in children. J Thorac Cardiovasc Surg 144:980–981CrossRefPubMed Rakhra SS, Brizard CP, d’Udekem Y, Konstantinov IE (2012) Valve-sparing aortic root replacement in children. J Thorac Cardiovasc Surg 144:980–981CrossRefPubMed
43.
Zurück zum Zitat Ramirez F, Pereira L (1999) Mutations of extracellular matrix components in vascular disease. Ann Thorac Surg 67:1857–1858CrossRefPubMed Ramirez F, Pereira L (1999) Mutations of extracellular matrix components in vascular disease. Ann Thorac Surg 67:1857–1858CrossRefPubMed
44.
Zurück zum Zitat Ramswamy P, Lytrivi ID, Nguyen K, Gelb BD (2006) Neonatal Marfan syndrome. Pediatr Cardiol 27:763–765CrossRef Ramswamy P, Lytrivi ID, Nguyen K, Gelb BD (2006) Neonatal Marfan syndrome. Pediatr Cardiol 27:763–765CrossRef
45.
Zurück zum Zitat Roman MJ, Rosen SE, Kramer-Fox R, Devereux RD (1993) Prognostic significance of the pattern of aortic root dilatation in the Marfan syndrome. J Am Coll Cardiol 22:1470–1476CrossRefPubMed Roman MJ, Rosen SE, Kramer-Fox R, Devereux RD (1993) Prognostic significance of the pattern of aortic root dilatation in the Marfan syndrome. J Am Coll Cardiol 22:1470–1476CrossRefPubMed
46.
Zurück zum Zitat Rozendaal L, Blom NA, Hilhorst-Hofstee Y, Ten Harkel ADJ (2011) Dilatation of the great arteries in an infant with Marfan syndrome and ventricular septal defect. Case Rep Med 1–5 Rozendaal L, Blom NA, Hilhorst-Hofstee Y, Ten Harkel ADJ (2011) Dilatation of the great arteries in an infant with Marfan syndrome and ventricular septal defect. Case Rep Med 1–5
47.
Zurück zum Zitat Ruzmetov M, Vijay P, Rodefeld MD, Turrentine MW et al (2006) Evolution of aortic valve replacement in children : a single experience. Int J Cardiol 113:194–200CrossRefPubMed Ruzmetov M, Vijay P, Rodefeld MD, Turrentine MW et al (2006) Evolution of aortic valve replacement in children : a single experience. Int J Cardiol 113:194–200CrossRefPubMed
48.
Zurück zum Zitat Segura AM, Luna RE, Horiba K, Stetler-Stevenson WG et al (1998) Immunohistochemistry of matrix metalloproteinases and their inhibitors in thoracic aortic aneurysms and aortic valves of patients with Marfan’s syndrome. Circulation 98(Suppl. 19):II331–337PubMed Segura AM, Luna RE, Horiba K, Stetler-Stevenson WG et al (1998) Immunohistochemistry of matrix metalloproteinases and their inhibitors in thoracic aortic aneurysms and aortic valves of patients with Marfan’s syndrome. Circulation 98(Suppl. 19):II331–337PubMed
49.
Zurück zum Zitat Shimizu H, Yozu R (2011) Valve-sparing aortic root replacement. Ann Thorac Cardiovasc Surg 17:330–336CrossRefPubMed Shimizu H, Yozu R (2011) Valve-sparing aortic root replacement. Ann Thorac Cardiovasc Surg 17:330–336CrossRefPubMed
50.
Zurück zum Zitat Strigl S, Quagebeur JM, Gersony WM (2007) Quadrivalvar replacement in infantile Marfan syndrome. Pediatr Cardiol 28:403–405CrossRefPubMed Strigl S, Quagebeur JM, Gersony WM (2007) Quadrivalvar replacement in infantile Marfan syndrome. Pediatr Cardiol 28:403–405CrossRefPubMed
51.
52.
Zurück zum Zitat Tierney ESS, Feingold B, Printz BF, Park SC et al (2007) Beta-blocker therapy does not alter the rate of aortic root dilation in pediatric patients with Marfan syndrome. J Pediatr 150:77–82CrossRef Tierney ESS, Feingold B, Printz BF, Park SC et al (2007) Beta-blocker therapy does not alter the rate of aortic root dilation in pediatric patients with Marfan syndrome. J Pediatr 150:77–82CrossRef
53.
Zurück zum Zitat Tweddell JS, Earing MG, Bartz PJ, Dunham-Ingles JL et al (2012) Valve-sparing aortic root reconstruction in children, teenagers and young adults. Ann Thorac Surg 94:587–591CrossRefPubMed Tweddell JS, Earing MG, Bartz PJ, Dunham-Ingles JL et al (2012) Valve-sparing aortic root reconstruction in children, teenagers and young adults. Ann Thorac Surg 94:587–591CrossRefPubMed
54.
Zurück zum Zitat van Karnebeek CDM, Naeff MSJ, Mulder BJM, Hennekam RCM et al (2001) Natural history of cardiovascular manifestations in Marfan syndrome. Arch Dis Child 84:129–137CrossRefPubMedCentralPubMed van Karnebeek CDM, Naeff MSJ, Mulder BJM, Hennekam RCM et al (2001) Natural history of cardiovascular manifestations in Marfan syndrome. Arch Dis Child 84:129–137CrossRefPubMedCentralPubMed
55.
Zurück zum Zitat Volguina IV, Miller DC, LeMaire SA, Palmero LC et al (2009) Valve-sparing and valve-replacing techniques for aortic root replacement in patients with Marfan syndrome: analysis of early outcome. Int J Cardiol 137:641–649 Volguina IV, Miller DC, LeMaire SA, Palmero LC et al (2009) Valve-sparing and valve-replacing techniques for aortic root replacement in patients with Marfan syndrome: analysis of early outcome. Int J Cardiol 137:641–649
56.
Zurück zum Zitat Williams A, Kenny D, Wilson D, Fagenello G et al (2012) Effects of atenolol, perindopril and verapamil on haemodynamic and vascular formation in Marfan syndrome—a randomised, double-blind, crossover trial. Eur J Clin Invest 42(8):891–899CrossRefPubMed Williams A, Kenny D, Wilson D, Fagenello G et al (2012) Effects of atenolol, perindopril and verapamil on haemodynamic and vascular formation in Marfan syndrome—a randomised, double-blind, crossover trial. Eur J Clin Invest 42(8):891–899CrossRefPubMed
57.
Zurück zum Zitat Wright MJ, Connolly HM, Otto CM, Yeon SB (2012) Genetics, clinical features, and diagnosis of Marfan syndrome and related disorders. (Uptodate) Wright MJ, Connolly HM, Otto CM, Yeon SB (2012) Genetics, clinical features, and diagnosis of Marfan syndrome and related disorders. (Uptodate)
58.
Zurück zum Zitat Wright MJ, Connolly HM, Otto CM, Yeon SB (2012) Management of Marfan syndrome and related disorders. (Uptodate) Wright MJ, Connolly HM, Otto CM, Yeon SB (2012) Management of Marfan syndrome and related disorders. (Uptodate)
59.
Zurück zum Zitat Yetman AT, Graham T (2009) The dilated aorta in patients with congenital cardiac defects. J Am Coll Cardiol 53:461–467CrossRefPubMed Yetman AT, Graham T (2009) The dilated aorta in patients with congenital cardiac defects. J Am Coll Cardiol 53:461–467CrossRefPubMed
60.
Zurück zum Zitat Yetman AT, Huang P, Bornemeier RA, McCrindle BW (2003) Comparison of Outcome of the Marfan syndrome in patients diagnosed at age ≤6 years versus those diagnosed at >6 years of age. Am J Cardiol 91:102–103CrossRefPubMed Yetman AT, Huang P, Bornemeier RA, McCrindle BW (2003) Comparison of Outcome of the Marfan syndrome in patients diagnosed at age ≤6 years versus those diagnosed at >6 years of age. Am J Cardiol 91:102–103CrossRefPubMed
Metadaten
Titel
Aortic Involvement in Pediatric Marfan syndrome: A Review
verfasst von
Omonigho Ekhomu
Zahra J. Naheed
Publikationsdatum
01.06.2015
Verlag
Springer US
Erschienen in
Pediatric Cardiology / Ausgabe 5/2015
Print ISSN: 0172-0643
Elektronische ISSN: 1432-1971
DOI
https://doi.org/10.1007/s00246-015-1101-0

Weitere Artikel der Ausgabe 5/2015

Pediatric Cardiology 5/2015 Zur Ausgabe

Die „Zehn Gebote“ des Endokarditis-Managements

30.04.2024 Endokarditis Leitlinie kompakt

Worauf kommt es beim Management von Personen mit infektiöser Endokarditis an? Eine Kardiologin und ein Kardiologe fassen die zehn wichtigsten Punkte der neuen ESC-Leitlinie zusammen.

Strenge Blutdruckeinstellung lohnt auch im Alter noch

30.04.2024 Arterielle Hypertonie Nachrichten

Ältere Frauen, die von chronischen Erkrankungen weitgehend verschont sind, haben offenbar die besten Chancen, ihren 90. Geburtstag zu erleben, wenn ihr systolischer Blutdruck < 130 mmHg liegt. Das scheint selbst für 80-Jährige noch zu gelten.

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Dihydropyridin-Kalziumantagonisten können auf die Nieren gehen

30.04.2024 Hypertonie Nachrichten

Im Vergleich zu anderen Blutdrucksenkern sind Kalziumantagonisten vom Diyhdropyridin-Typ mit einem erhöhten Risiko für eine Mikroalbuminurie und in Abwesenheit eines RAS-Blockers auch für ein terminales Nierenversagen verbunden.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.